 |
110 Diseases |  |
151 Trials |
|
151 Trials |  |
7120 News |  |
| «12...56789101112131415...8687» |
- | Prolia (denosumab) / Amgen
Journal: Giant Cell Tumor of Mandible : A Case Report. (Pubmed Central) - Apr 3, 2024
After exclusion of distant metastasis by F-18 FDG PET scan, she underwent en-bloc resection of the tumor with free fibula flap reconstruction. During 6 months of follow up visit patient had no recurrence.
- | Prolia (denosumab) / Amgen
Journal: Recurrent Giant Cell Tumor of Sphenoid Bone: A Rare Finding. (Pubmed Central) - Apr 3, 2024
Here, we describe a case of recurrent giant cell tumor of sphenoid bone in a young male, who underwent surgical resection twice, after which he was advised adjuvant radiotherapy and denosumab. The patient did not take radiotherapy.
- | Prolia (denosumab) / Amgen, Tagrisso (osimertinib) / AstraZeneca
Retrospective data, Journal: Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy. (Pubmed Central) - Apr 2, 2024
The presence of BoM is a negative prognostic factor for NSCLC patients with an EGFR mutation, possibly due to the presence of extrathoracic metastases. However, adding AAT and denosumab, along with sequential osimertinib, to the treatment regimen for patients with BoM can improve survival outcomes.
- | Prolia (denosumab) / Amgen
Observational data, Journal: Long-term effects of denosumab on bone mineral density and turnover markers in patients undergoing hemodialysis. (Pubmed Central) - Apr 1, 2024
However, adding AAT and denosumab, along with sequential osimertinib, to the treatment regimen for patients with BoM can improve survival outcomes. The study showed long-term suppression of TRACP-5b and BAP levels and sustaining BMD after denosumab administration over an extended period in patients undergoing hemodialysis.
- || Prolia (denosumab) / Amgen
P2 data, Journal: Effect of denosumab on inflammation and bone health in active Charcot foot: A phase II randomised controlled trial. (Pubmed Central) - Apr 1, 2024
Denosumab ameliorated the early decline in calcaneal Stiffness Index associated with active CN. However, no difference in normalisation of foot temperature was observed.
- | Prolia (denosumab) / Amgen
Journal: Cancer risk in patients treated with denosumab compared with alendronate: A population-based cohort study. (Pubmed Central) - Apr 1, 2024
However, no difference in normalisation of foot temperature was observed. There was no difference in the risk of cancer following treatment with denosumab compared to treatment with alendronate assessed after a short follow-up of 3
- | Prolia (denosumab) / Amgen, Edirol (eldecalcitol) / Roche, Taisho
Retrospective data, Journal: Zinc improves Denosumab and eldecalcitol efficacy for bone mineral density in patients with hypozincemia. (Pubmed Central) - Apr 1, 2024
There was no difference in the risk of cancer following treatment with denosumab compared to treatment with alendronate assessed after a short follow-up of 3 Hypozincemia may reduce the efficacy of DMAb and eldecalcitol in increasing BMD and fracture prevention.
- || Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Review, Journal: Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe. (Pubmed Central) - Mar 29, 2024
Since these two chronic diseases frequently co-exist, there are data suggesting that anti-osteoporosis treatments may affect NAFLD progression by impacting on its pathogenetic mechanisms. In the present review, we present on overview of the current understanding of the liver-bone cross talk and summarize the experimental and clinical evidence correlating NAFLD and osteoporosis, focusing on the possible effects of anti-osteoporotic drugs on NAFLD.
- | Prolia (denosumab) / Amgen, Kadcyla (ado-trastuzumab emtansine) / Roche
Journal, Metastases: Recurrent severe hypocalcemia following chemotherapy regimen changes in advanced breast cancer: two case reports. (Pubmed Central) - Mar 29, 2024
It is possible that antitumor drugs affect calcium and bone metabolism associated with bone metastases. While these cases are rare, it is crucial for oncologists to be aware of hypocalcemia not only at the initiation of bone-modifying agents but also throughout the entire antitumor therapy, as hypocalcemia can lead to fatal outcomes.
- methotrexate / Generic mfg.
INSUFFICIENCY FRACTURES IN INFLAMMATORY ARTHRITIS PATIENTS (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_2578;
Methotrexate was stopped and she had Pamidronate...He was initially treated with Alendronate, then zoledronate and later teriparatide...She was treated with teriparatide, denosumab and then zoledronate...Stopping Methotrexate is helpful, but some patients may require anabolic and/or anti-resorptive drugs. Figure 1.
- Prolia (denosumab) / Amgen
THE RISK OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW (MRONJ) IN A PATIENT WITH OSTEOPOROSIS TREATED WITH ANTI-RESORPTIVE THERAPY AND UNDERGOING DENTAL CARE IS NEGLIGIBLE WITH A CTX THRESHOLD ABOVE 250 (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_2236;
For patients undergoing oral bisphosphonate treatment for osteoporosis, a threshold of 250 mg/mL is linked to an almost negligible risk (beyond the 99th percentile) of experiencing MRONJ. Figure 1.
- Tavneos (avacopan) / Amgen
SAFETY AND EFFECTIVENESS OF AVACOPAN BEYOND 52 WEEKS: EXPERIENCE TO DATE IN THE EARLY ACCESS PROGRAM (EAP) (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1721;
These results confirm that avacopan has a manageable safety profile with the potential to be effective beyond 52 weeks in sustaining disease control. Limitations of this analysis include potential underreporting, incomplete data and no control group.
- Prolia (denosumab) / Amgen
REMARKING THE OSTEOPOROSIS IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS (AAV): DATA FROM EASTERN MEDITERRANEAN (TRVAS) (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1713;
It also suggested that the prevalence of osteoporosis in AAV patients was much higher (80%) compared to the general population. Physicians should consider the evaluation and treatment of secondary osteoporosis in the management of AAV to decrease the risk of osteoporotic fracture, a severe comorbidity.
- Prolia (denosumab) / Amgen
COMPARATIVE EFFECTIVENESS OF DENOSUMAB VERSUS ZOLEDRONIC ACID AMONG POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN THE U.S. MEDICARE PROGRAM (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1171;
Physicians should consider the evaluation and treatment of secondary osteoporosis in the management of AAV to decrease the risk of osteoporotic fracture, a severe comorbidity. In a cohort of over 125,000 treatment-naive women with PMO, we observed robust, clinically meaningful reductions in the risk of MOP, hip, NV, and NHNV fractures for patients on Dmab compared to ZA, with greater reductions in fracture risk with longer duration of exposure.
- Prolia (denosumab) / Amgen
STUDY OF BONE METABOLISM IN PATIENTS DIAGNOSED WITH OSTEOGENESIS IMPERFECTA (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1166;
Nearly all have a history of previous fractures and demonstrate bone mineral density (BMD) within the range of osteoporosis. The most commonly used treatments are bisphosphonates, with pamidronate in pediatric cases and zoledronic acid in adults being the predominant choices.
- Prolia (denosumab) / Amgen
LONG-TERM BONE MINERAL DENSITY CHANGES IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH DENOSUMAB: QUASI-EXPERIMENTAL STUDY (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1165;
The most commonly used treatments are bisphosphonates, with pamidronate in pediatric cases and zoledronic acid in adults being the predominant choices. four years of denosumab therapy were associated with increased BMD in KTRs, while untreated KTRs showed significant BMD losses at all sites.
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
EFFICACY ANALYSIS OF ROMOSOZUMAB TREATMENT FOR OSTEOPOROSIS WITH HIGH RISK OF FRACTURE, FOCUSING ON CHANGES IN BONE MINERAL DENSITY DURING THE FIRST SIX MONTHS AND THE SECOND SIX MONTHS (Poster Tour 3) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1146;
We observed that LS-BMD was included in II group with a high probability. On the other hand, we observed that a certain number of DD groups occurred regarding TH-BMD.
- Prolia (denosumab) / Amgen
PHARMACOLOGICAL UNDERTREATMENT OF HIP FRAGILITY FRACTURES IN THE PRIMARY CARE SETTING: A 3-YEAR PORTUGUESE NATIONWIDE PERSPECTIVE (Poster Tour 3) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1145;
On the other hand, we observed that a certain number of DD groups occurred regarding TH-BMD. RS - sodium risedronate; AA - alendronic acid; AI - ibandronic acid; AZ - zoledronic acid; T - teriparatide; D - denosumab; R
- Prolia (denosumab) / Amgen
COMPARATIVE EFFECTIVENESS OF DENOSUMAB VERSUS BISPHOSPHONATES AMONG TREATMENT-EXPERIENCED POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN THE U.S. MEDICARE PROGRAM (Poster Tour 3) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1144;
66 years of age with prior history of treatment with an oral BP, who newly initiated Dmab (n~108,000), a different oral BP (alendronate, ibandronate, or risedronate; n=100,649), alendronate (Aln; n=53,165), or zoledronic acid (ZA; n=35,100) between Jan 1, 2012 to Dec 31, 2018 were followed from treatment initiation (index date) until the first instance of a fracture, treatment discontinuation (defined as the end of exposure + 60-day gap) or switch, Medicare disenrollment, death, end of available data (Dec 31, 2019), or 5 years post-index date. In a large cohort of treatment-experienced women with PMO, we observed robust, clinically meaningful reductions in the risk of hip, NV, NHNV, HV, and MOP fractures for patients on Dmab compared to oral BP, Aln, and ZA; greater reductions in fracture risk were observed with longer duration of exposure.
- Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
ROMOSOZUMAB AND DENOSUMAB COMBINATION THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS (Poster Tour 3) - Mar 29, 2024 - Abstract #EULAR2024EULAR_1142;
Romosozumab added to ongoing denosumab resulted in an increase in P1nP and lumbar spine BMD, but not in femoral neck BMD. For patients on denosumab, using romosozumab as an additional treatment appeared to be useful in terms of bone formation markers and spine BMD versus denosumab alone.
- Prolia (denosumab) / Amgen
NATIONWIDE EPIDEMIOLOGY OF FRACTURE INCIDENCE IN PATIENTS TREATED WITH DENOSUMAB: DATA ON 271 295 PATIENTS FROM THE FRENCH HEALTHCARE INFORMATION SYSTEM (A8.1) - Mar 29, 2024 - Abstract #EULAR2024EULAR_944;
This nationwide study demonstrates that cessation of Denosumab is associated with an increased fracture risks and that an immediate relay with bisphosphonate is often poorly executed, despite recommendations. Further investigations are needed to confirm and elucidate the determinants of these findings.
- Prolia (denosumab) / Amgen
ANTIRESORPTIVE MEDICATION-RELATED JAW OSTEONECROSIS: AN EUROPEAN EUDRAVIGILANCE DATABASE-BASED RETROSPECTIVE COHORT STUDY (A8.1) - Mar 29, 2024 - Abstract #EULAR2024EULAR_942;
However, indication for the use of zoledronate was mostly an oncologic context, which implies a more intensive treatment; therefore, our findings must be interpreted with caution. JON accounted for 12.5% to 17.9% of all SARs, in line with the current evidence of its infrequent occurrence.
- prednisone / Generic mfg.
GLUCOCORTICOID INDUCED OSTEOPOROSIS: PROPHYLAXIS HABITS IN PATIENTS TREATED WITH HIGH-DOSE PREDNISONE (A8.1) - Mar 29, 2024 - Abstract #EULAR2024EULAR_941;
However, in the whole sample analyzed, only one in 7 patients received OP prophylaxis. Update sessions on management of glucocorticoid-induced osteoporosis and other actions are needed for the specialties that employ high-dose GC.
- Prolia (denosumab) / Amgen
RISK OF FRAGILITY FRACTURE AFTER LONG-TERM DISCONTINUATION OF OSTEOPOROSIS TREATMENT IN POST-MENOPAUSAL OSTEOPOROSIS WOMEN IN FRANCE: A POPULATION-BASED STUDY CONDUCTED ON THE NATIONWIDE CLAIM DATABASE (SNDS) (A8.1) - Mar 29, 2024 - Abstract #EULAR2024EULAR_939;
While not recommended, 42.5% of women initiating Dmab discontinued treatment for at least one year, which almost doubled their fracture risk. No increased risk was observed for long term discontinuation of IV BP.
- Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
GENDER DISPARITIES IN OSTEOPOROSIS DIAGNOSIS AND MANAGEMENT AMONG PATIENTS WITH VERTEBRAL FRACTURES: INSIGHTS FROM A LARGE-SCALE DATABASE STUDY (A8.1) - Mar 29, 2024 - Abstract #EULAR2024EULAR_938;
Women were more likely than men to be diagnosed with and treated for osteoporosis. These findings suggest a potential underdiagnosis and undertreatment of osteoporosis in men with vertebral fractures, underscoring the need for more vigilant screening and management strategies in this demographic.
- | Prolia (denosumab) / Amgen
Journal: Medication-related osteonecrosis of the jaw in a paediatric patient taking denosumab: a case report. (Pubmed Central) - Mar 27, 2024
Review of the literature, however, reveals no reported paediatric MRONJ cases to date. We present such a case in a nine-year-old female patient with a vertebral aneurysmal bone cyst, who received dental extractions subsequent to denosumab therapy.
- || Prolia (denosumab) / Amgen
Retrospective data, Review, Journal: Effectiveness of fracture liaison service in reducing the risk of secondary fragility fractures in adults aged 50 and older: a systematic review and meta-analysis. (Pubmed Central) - Mar 27, 2024
More high-quality studies in this field could improve the certainty of the evidence. Review registration: PROSPERO-CRD42021266408.
- | Prolia (denosumab) / Amgen
Journal: Efficacy of denosumab against osteoporosis determined using quantitative computed tomography in treatment-na (Pubmed Central) - Mar 26, 2024
Review registration: PROSPERO-CRD42021266408. No abstract available
- || Prolia (denosumab) / Amgen
Review, Journal: A narrative review of the pharmaceutical management of osteoporosis. (Pubmed Central) - Mar 26, 2024
Hormonal therapies are used if patients cannot tolerate bisphosphonates or denosumab or are refractory to these medications. Preventative measures for osteoporosis include tailored exercise and sufficient intake of calcium and vitamin D via diet or supplementation.
- |||| CMAB807 (denosumab biosimilar) / 3SBio
Trial completion date, Trial primary completion date: Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia (clinicaltrials.gov) - Mar 26, 2024
P3, N=278, Recruiting, Sponsor: Shanghai Biomabs Pharmaceutical Co., Ltd.
Preventative measures for osteoporosis include tailored exercise and sufficient intake of calcium and vitamin D via diet or supplementation. Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
- |||| Prolia (denosumab) / Amgen
New P4 trial: Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China (clinicaltrials.gov) - Mar 25, 2024
P4, N=100, Not yet recruiting, Sponsor: Amgen
- | Prolia (denosumab) / Amgen
Journal: Management of Vertebral Fragility Fracture in Older People: Recommendations from a Spanish Consensus of Experts. (Pubmed Central) - Mar 25, 2024
Participants agreed on the administration of teriparatide for 24 months and then a switch to denosumab or bisphosphonates in patients at high risk of fracture...Although there was multidisciplinary agreement on diagnostic tests and non-pharmacological and pharmacological treatment in frail older people, therapeutic objectives should be individualized for every patient. In addition to the specific recommendations, close collaboration between the geriatrician and the primary care physician is essential for the optimal chronic management of frail patients with fragility fractures.
- | Prolia (denosumab) / Amgen
Journal: Denosumab in the treatment of osteoporosis associated with chronic kidney disease. (Pubmed Central) - Mar 25, 2024
In addition to the specific recommendations, close collaboration between the geriatrician and the primary care physician is essential for the optimal chronic management of frail patients with fragility fractures. No abstract available
- || Prolia (denosumab) / Amgen
P2a data, Journal: RANKL blockade for erosive hand osteoarthritis: a randomized placebo-controlled phase 2a trial. (Pubmed Central) - Mar 25, 2024
P2
These results demonstrate that denosumab has structure modifying effects in erosive hand OA by inducing remodeling and preventing new erosive joints. EU Clinical Trials Register identifier 2015-003223-53 .
- cinacalcet HCl / Generic mfg.
Nephrogenic Diabetes Insipidus secondary to Hypercalcemia of Malignancy responsive to Cinacalcet () - Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_541;
Ionized calcium remained the same despite Zometa, calcitonin, denosumab, and aggressive IVF with NS...Desmopressin was then initiated but did not sufficiently concentrate the urine... This case exhibits the potential use of cinacalcet for the treatment of nephrogenic DI secondary to hypercalcemia of malignancy.
- Libtayo (cemiplimab-rwlc) / Regeneron
A case of cemiplimab-induced hypercalcemia in metastatic squamous cell carcinoma () - Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_504;
It is important to recognize ICI-associated hypercalcemia. Ongoing research is imperative to understand the underlying mechanisms and the optimal approaches to management.
- | Prolia (denosumab) / Amgen
Enrollment closed, Head-to-Head: REDUSE: Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks (clinicaltrials.gov) - Mar 21, 2024
P3, N=1380, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Ongoing research is imperative to understand the underlying mechanisms and the optimal approaches to management. Recruiting --> Active, not recruiting
- | Prolia (denosumab) / Amgen
Trial completion date, Trial primary completion date: Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations. (clinicaltrials.gov) - Mar 21, 2024
P=N/A, N=100, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2025
- || abiraterone acetate / Generic mfg.
Clinical, Journal, Metastases: Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated With Abiraterone Acetate. (Pubmed Central) - Mar 19, 2024
The association between the use of bone-modifying agents (BMAs) and the outcomes among patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with abiraterone acetate plus prednisone (AAP) remains unclear...Use of BMAs was defined as the administration of bisphosphonates and denosumab within 90 days before and after randomization...Zoledronic acid was the most frequently administered BMA in both the AAP (93 [70.5%]) and the ADT (88 [67.2%]) cohorts...No evidence was found that the outcomes of BMA varied by AAP or ADT (hazard ratio for time to SRE, 0.99 [95% CI, 0.48-2.08]; P?=?.99 for interaction; hazard ratio for OS, 1.31 [95% CI, 0.88-1.96]; P?=?.18 for interaction). The findings of this cohort study suggest that use of BMAs was associated with a longer time to SRE in patients with high-risk mCSPC treated with ADT, with or without AAP, suggesting that BMA use might provide benefits to this population.
- || Review, Journal: The interplay of rheumatoid arthritis and osteoporosis: exploring the pathogenesis and pharmacological approaches. (Pubmed Central) - Mar 19, 2024
This review will shed light on the relationship between osteoporosis and rheumatoid arthritis as well as the various factors that influence the onset of osteoporosis in RA patients. We also explore several treatment approaches to effectively managing osteoporosis in RA patients.
- Prolia (denosumab) / Amgen
Incidence, risk factors and management of medication-related osteonecrosis of the jaw in breast cancer patients treated with Zoledronic Acid or Denosumab over a 5-year period in a UK tertiary institution (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_523;
Dental intervention during BMA treatment was our principal risk factor. High-level evidence regarding drug holidays prior to dental intervention is required.
- | Prolia (denosumab) / Amgen
Trial completion date, Trial primary completion date: Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia (clinicaltrials.gov) - Mar 18, 2024
P2, N=15, Recruiting, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
High-level evidence regarding drug holidays prior to dental intervention is required. Trial completion date: Dec 2026 --> Jun 2024 | Trial primary completion date: Dec 2026 --> Jun 2024
- ||| HLX14 (denosumab biosimilar) / Fosun Pharma, Organon
Trial completion: Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia (clinicaltrials.gov) - Mar 18, 2024
P1, N=252, Completed, Sponsor: Shanghai Henlius Biotech
Trial completion date: Dec 2026 --> Jun 2024 | Trial primary completion date: Dec 2026 --> Jun 2024 Recruiting --> Completed
- || Prolia (denosumab) / Amgen
Review, Journal: Multicentric carpotarsal osteolysis syndrome with variants of MAFB gene: a case report and literature review. (Pubmed Central) - Mar 18, 2024
Recruiting --> Completed This suggests that MRI examination and whole exome sequencing should be considered when MCTO is suspected, and Denosumab might be an option in the treatment of MCTO.
- |||||||||| Prolia (denosumab) / Amgen, Jinlisheng (narlumosbart) / CSPC Pharma
New P3 trial, Head-to-Head: Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease (clinicaltrials.gov) - Mar 18, 2024
P3, N=478, Not yet recruiting, Sponsor: RenJi Hospital
- || Prolia (denosumab) / Amgen
Review, Journal: Evidence-Based Guideline for the management of osteoporosis in men. (Pubmed Central) - Mar 15, 2024
This suggests that MRI examination and whole exome sequencing should be considered when MCTO is suspected, and Denosumab might be an option in the treatment of MCTO. The recommendations are based on a comprehensive review of the latest research related to diagnostic and screening approaches for osteoporosis and its
- | Prolia (denosumab) / Amgen
Enrollment change, Trial termination: The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury (clinicaltrials.gov) - Mar 15, 2024
P4, N=5, Terminated, Sponsor: James J. Peters Veterans Affairs Medical Center
The recommendations are based on a comprehensive review of the latest research related to diagnostic and screening approaches for osteoporosis and its N=32 --> 5 | Recruiting --> Terminated; Study ended early due to COVID-19
- ||| Prolia (denosumab) / Amgen
New P1 trial: Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia (clinicaltrials.gov) - Mar 14, 2024
P1, N=225, Not yet recruiting, Sponsor: Xentria, Inc.
- Prolia (denosumab) / Amgen
Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer - Time to Event analysis from the GeparX 2 (Hamburg Hall) - Mar 14, 2024 - Abstract #ESMOBC2024ESMO_BC_236;
- Prolia (denosumab) / Amgen
Management of Chronic Pain and Overall Mortality in Metastatic Renal Cell Carcinoma: A Multicenter Investigation from a Large Global Health Research Network (TriNetX) (221C) - Mar 12, 2024 - Abstract #AUA2024AUA_1167;
Patients receiving opioids were identified by searching the following: hydrocodone, hydromorphone, morphine, codeine, tramadol, oxycodone, and naloxone (proxy for opioid prescription)... RCC with BM has an overall poor prognosis